Influence
July 6, 2020

Pandemic spotlights nursing home needs; Regenstrief scientist leading company to address the gaps

Probari, Inc., a company dedicated to improving nursing home care and led by Regenstrief research scientist and Indiana University School of Medicine associate professor Kathleen Unroe, M.D., MHA, was highlighted in Inside Indiana Business. The COVID-19 pandemic has exposed many areas of weakness within the nursing home system, areas that Probari is working to address.

“The problems we are trying to address with our startup were problems a year ago, 10 years ago,” Dr. Unroe told IIB. “But now, because of the extreme vulnerability of this population, there’s a bright light shining on how we can’t tolerate not having the best possible communication lines among all stakeholders in nursing facilities; we can’t tolerate not doing high-quality advanced care planning for all residents, and we must catch an acute change in status as soon as it happens.”

Dr. Unroe is the founder of Probari, and Regenstrief Institute is an investor in the company. The company uses a care model the embeds a specially trained nurse in each facility. The model was proven to be successful during a Centers for Medicare and Medicaid Services demonstration project.

In April 2020, the Indiana State Department of Health partnered with Probari to provide support to more than 500 nursing homes across the state during the pandemic.

Read more about the work of Probari

Related News

(From left to right) Dr. Brian Dixon, Dr. Sanji De Sylva and Isaac Vetter. Photo credit: Svetlana Efimova

Regenstrief experts advance global dialogue on digital health and interoperability at forum in Dubai

Regenstrief informaticians joined global leaders who shared their expertise at the 8th ZIMAM Digital Health Forum November 5-6, in

Regenstrief researchers join national stage to advance aging and gerontology research

Regenstrief Institute research scientists joined leading experts from across the nation at the Gerontological Society of America (GSA) 2025

illustration of the combination of interventions used in the D3 pragmatic clinical trial

Zero-cost, AI-driven digital detection identifies Alzheimer’s and related dementias without additional clinician time

Few primary care practices are designed for the timely detection of Alzheimer’s disease and related dementias. The limited time